Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prevalence of purchase of antihypertensive and serum lipid-reducing drugs in Sweden--individual data from national registers.
Nordic Council of Ministers, Nordic School of Public Health NHV.
Nordic Council of Ministers, Nordic School of Public Health NHV.
Nordic Council of Ministers, Nordic School of Public Health NHV.
2008 (English)In: Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, E-ISSN 1099-1557, Vol. 17, no 1, 37-42 p.Article in journal (Refereed) Published
Abstract [en]

PURPOSE: To determine the prevalence of purchase of prescribed antihypertensive and/or serum lipid-reducing pharmaceutical preparations among different age groups, from the age of 45, in the Swedish population. Further, to calculate the percentage of the population, from the age of 60, who purchased these pharmaceuticals without having had a circulatory diagnosis in the Hospital Discharge Register the last 7 years, or having purchased nitrate vasodilators, as an attempt to estimate the proportion of primary preventive treatments.

METHODS: A cross-sectional study, of individual data on prescriptions for antihypertensives (C02-C03, C07-C09) and serum lipid-reducing agents (C10), dispensed from July to December 2005 for the Swedish population. Data were obtained from the new Swedish Prescribed Drugs Register. The data were related to population statistics, and linked to data on diagnoses of cardiovascular disease (I00-I99), from the Swedish Hospital Discharge Register 1998-2004. Data on individuals with purchase of antihypertensive or serum lipid-reducing agents, but without a diagnosis of cardiovascular disease, were also linked to purchase of nitrate vasodilators (C01D).

RESULTS: Among Swedes of 60 years and above, 53% purchased antihypertensive or serum lipid-reducing pharmaceuticals, and 30% purchased the pharmaceuticals without having been hospitalized for a coronary or cerebrovascular event during the previous 7 years, or having purchased prescribed nitrate vasodilators during 6 months.

CONCLUSION: Over half of the Swedish senior population purchased prescribed antihypertensive or serum lipid-reducing drugs during 6 months in 2005. The magnitude of the prevalence points to the importance of intensified follow-up of both adverse effects and of effectiveness of these drugs.

Place, publisher, year, edition, pages
2008. Vol. 17, no 1, 37-42 p.
Keyword [en]
Drug Prevalence, Caridovascular disease, primary Prevention, Antihypertesive, Serum Lipid-Reducing, Sweden, Drug Use, Elderly
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:norden:org:diva-3423DOI: 10.1002/pds.1515PubMedID: 17987590OAI: oai:DiVA.org:norden-3423DiVA: diva2:749273
Available from: 2014-09-23 Created: 2014-09-23 Last updated: 2014-09-23Bibliographically approved
In thesis
1. Public Health Aspects of Pharmaceutical Prescription Patterns: Exemplified by treatments for prevention of cardiovascular disease
Open this publication in new window or tab >>Public Health Aspects of Pharmaceutical Prescription Patterns: Exemplified by treatments for prevention of cardiovascular disease
2007 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Public health aspects of pharmaceutical prescription patterns: Exemplified by treatments for prevention of cardiovascular disease. Louise Silwer. ISBN: 978-91-85721-18-4 ISSN: 0283-1961Main aim:To study patterns and trends of dispensed prescriptions, to explore what proportion of the population is exposed to some of the more prevalently prescribed pharmaceuticals, and to find possible ways of measuring drug-induced adverse symptoms in the population. Further, to illuminate conditions surrounding prescribing in primary prevention of cardiovascular disease. Methods: In three descriptive studies of prescription patterns, prescription data at aggregate level from a Swedish county were analysed retrospectively, and proportions were calculated. Data from the first ten years of the studies were obtained from a local prescription study, and data from another five years were local data from a national prescription survey. Data from a Danish database (OPED), with data at the individual level, were used for a prescription sequence symmetry analysis, and when Swedish national prescription data at the individual level became accessible, they were used for calculations of drug prevalence in the entire Swedish population. In a qualitative analysis of interview data, a phenomenographic approach was used. Main results: The purchase of pharmaceuticals on prescription almost doubled in the studied county in the period 1988-2002. Some common pharmaceuticals that increased to a great extent among the older part of the population were cardiovascular preventive drugs, such as antihypertensive and lipid modifying agents, and also hormone replacement therapy for women. In 2005, over half of all Swedish citizens, aged 60 or over, purchased antihypertensive or lipid modifying preparations during a six-month period. The different views that were found among GPs, regarding beliefs and practical management of primary prevention of CVD, could be interpreted as a reflection of the complexity of patient counselling in primary prevention in practice. Conclusion: The increase in dispensed prescriptions over the 15 years and the magnitude of the prevalence of the studied pharmaceuticals, such as antihypertensive, lipid modifying and hormonal treatments, which to a great extent are used by ‘healthy’ people, point to the need of following-up both beneficial and harmful consequences on public health. The prevalence of preventive treatments together with the variation in views of administration of primary prevention of cardiovascular disease, also point to the need of clarification of guidelines regarding pharmaceutical primary prevention and encouragement of therapy discussions among GPs.

Place, publisher, year, edition, pages
Göteborg: Nordic School of Public Health NHV Göteborg, Sweden, 2007. 61 p.
Series
NHV Reports and Doctor of Public Health-Theses, ISSN 0283-1961 ; NHV Rapport 2007:4
Keyword
pharmacoepidemiology, prevalence, drug use, adverse effects, primary care, primary prevention, cardiovascular, antihypertensives, lipid modifying agents, public health, Sweden
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:norden:org:diva-3425 (URN)978-91-85721-18-4 (ISBN)
Public defence
2007-09-25, Nordic School of Public Health NHV, Göteborg, Sweden, 13:00 (English)
Opponent
Supervisors
Available from: 2014-09-23 Created: 2014-09-23 Last updated: 2014-09-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Nordic School of Public Health NHV
In the same journal
Pharmacoepidemiology and Drug Safety
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 34 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf